DK_CHMP_Trastuzumab Deruxtecan EU CHMP Announcement_edit 10122020_20.20 - Kopi (2).pdf

Dokument -

DK_CHMP_Trastuzumab Deruxtecan EU CHMP Announcement_edit 10122020_20.20 - Kopi (2).pdf

  • Licens: Brug i medier
    Materialet kan downloades af journalister, bloggere, meningsdannere etc. Det kan bruges og deles i forskellige sociale medier-kanaler med det formål fremføre, fortælle, kommentere eller redegøre for jeres pressemeddelelser og andre publiceringer - forudsat at materialet er uredigeret og publiceret i sin helhed. Forfatteren eller skaberen af materialet skal krediteres i det omfang, som god skik kræver (det betyder f.eks. at fotografer skal krediteres).
  • Filformat: .pdf
Download

Emner

  • Sygdomme

Kontakt

Camilla Grüning

Pressekontakt Associated Product Manager

Relateret materiale

Trastuzumab Deruxtecan Recommended for Conditional Marketing Authorization in the EU by CHMP for HER2 Positive Metastatic Breast Cancer

Trastuzumab Deruxtecan Recommended for Conditional Marketing Authorization in the EU by CHMP for HER2 Positive Metastatic Breast Cancer Recommendation based on positive results from the DESTINY-Breast01 trial, which showed durable responses in patients with previously treated disease See attached press release